3rd annual listing of In Vivo, Citeline Commercial ‘Rising Leaders’ 📰 🏅 Trellus Health Co-Founder Laurie Keefer nominated by Lucie Ellis-Taitt as one of the entrepreneurs and innovators from across the world who represent the next wave of creativity in health care 🏥 invivo.pharmaintelligence.informa.com/IV125039/In-Vi…

Another Blow To Aduhelm As Biogen Withdraws EU Filing bit.ly/3Ke3ZmT #PharmaScrip

Bernstein's Ronny Gal is joining $NVS as chief strategy & growth officer from August. Big move!

Biotech firm OMass Therapeutics today completed an impressive $100m series B round. CEO Ros Deegan, one of In Vivo’s 2022 rising leaders, believes the firm’s proprietary technology platform could open the door to an innovative approach to drug discovery. invivo.pharmaintelligence.informa.com/IV125070/OMass…

2021 Global Biopharma R&D Productivity And Growth Ranking bit.ly/3yhv5qH

(1/2) Here's two stories looking at recent filings and approval #pinksheet #pharma: Story 1 is the nearly weekly keeping track: Keeping Track: AZ’s Busy Oncology Biz, Phathom’s Voquezna Approval, And A Trio Of Complete Response Letters pink.pharmaintelligence.informa.com/articles/2022/…

(2/2) Story 2 is a look at breakthrough designations ... #pinksheet #pharma: pink.pharmaintelligence.informa.com/PS146147/Recen…

Roche TIGIT SKYSCRAPER-01 failed (on PFS). Ugh

Roche has suffered a major setback in its goal to lead in a new class of cancer immunotherapies, with the surprise failure of its anti-TIGIT tiragolumab in non-small cell lung cancer. scrip.pharmaintelligence.informa.com/SC146361/Blow-…

After years of the front runners struggling to overcome problems with allogeneic or ‘off-the-shelf’ CAR-T therapies, Caribou Biosciences has unveiled early data which suggest it may just have cracked the challenge with its candidate CB-010. scrip.pharmaintelligence.informa.com/SC146378/PD-1-…

Elizabeth Jungman: Interpreter Of The FDA’s Policy Crystal Ball bit.ly/3Mpjo5v

China Takes A Bigger Role In The World Pharma Stage bit.ly/3wqvMwr

Europe’s Big Pharma Players Begin Tricky 2022 In Style bit.ly/3NndvGe

Trial Hot Spot: Australia's Attractions To The Korean Industry bit.ly/3yMO10E #PharmaScrip

Interesting chat at #LSXworld this morning. Novo Nordisk's John McDonald says the company will no longer be a "window shopper". Looking to partner earlier to grow pipeline but staying well away from oncology.

#LSXworld "We are excited about platforms... Novo Nordisk is most interested in gene editing deals." Comments from John McDonald.

Top 30 leaders: see the list of industry influencers highlighted in the fourth edition of In Vivo's Rising Leaders series. invivo.pharmaintelligence.informa.com/IV147718/In-Vi…

For In Vivo’s Rising Leaders Lucie Ellis-Taitt chats with Amira Barkal, MD/PhD about how she “dreams big and is fearless,” taking down barriers as she leads Pheast’s #CD24 program at the same time as she helps #cancer patients as a resident physician. In Vivo, Citeline Commercial: bit.ly/3r5i7L9

'INFEX Therapeutics CEO Dr Pete Jackson caught up with Lucie Ellis-Taitt on the In Vivo, Citeline Commercial podcast to discuss the new UK Antibiotics Reimbursement Plan He also spoke about: 📈INFEX Therapeutics's evolution to clinical-stage biotech 🦠Lessons learnt from #COVID19 #INFX invivo.pharmaintelligence.informa.com/IV148513/Podca…

An estimated 64 priority review vouchers have been issued by the US FDA since the scheme started in 2007. 25 vouchers have been claimed. invivo.pharmaintelligence.informa.com/IV148526/Major…